Revisiting the use of capecitabine in the era of immunotherapy: Efficacy as second-line and later therapy in recurrent/metastatic head and neck squamous cell carcinoma. - Ma J; Brooks C; Tasoulas J; Wind LS; Sheth S; Gwynn M (Oral oncology, 2025)